Results 151 to 160 of about 116,720 (351)
Evaluation of the performance of ChatGPT‐4 and ChatGPT‐4o as a learning tool in endodontics
Abstract Aims The aim of this study was to evaluate the accuracy and consistency of responses given by two different versions of Chat Generative Pre‐trained Transformer (ChatGPT), ChatGPT‐4, and ChatGPT‐4o, to multiple‐choice questions prepared from undergraduate endodontic education topics at different times of the day and on different days ...
Esra Arılı Öztürk +2 more
wiley +1 more source
Fully quantitative, mass‐standardised, antibody responses to ten SARS‐CoV‐2 variants show significant variation in immunity profiles or endotypes. The incidence of the complete response to all variants is significantly improved after three vaccinations.
Philip H. James‐Pemberton +6 more
wiley +1 more source
An Insidious Source of Chronic Sinusitis and Recurrent Epistaxis: A Rare Case of Skull Base Glomangiopericytoma [PDF]
Ismail Ozgenc +4 more
openalex +1 more source
Patients' Experiences of Day Surgery: A Qualitative Systematic Review
ABSTRACT Aim To examine how patients experience day surgery. Design Systematic review using Thomas and Harden's framework for synthesis and analysed through Ricoeur's theory of interpretation. Methods and Data Sources Systematic searches in MEDLINE, CINAHL and EMBASE (September 2023) identified qualitative studies focusing on patients' lived ...
Josephine Ransborg Sig +4 more
wiley +1 more source
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin +24 more
wiley +1 more source
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui +15 more
wiley +1 more source
The TRIP database showed most Acute Respiratory Infections questions were already addressed by Cochrane reviews [PDF]
Brassey, Jon +4 more
core +1 more source
Effectiveness of Oral Steroid Administration for Eosinophilic Sinusitis
Kousuke Yoshifuku +2 more
openalex +2 more sources
ABSTRACT Introduction Pneumonia is a leading cause of death for people with intellectual and developmental disabilities (IDD), who also have increased risk of oral disease. Given the known relationship between oral disease and pneumonia in similar populations, this review aims to explore what is known about the association between oral health and ...
Katrina Byrne +7 more
wiley +1 more source

